Showing 20 of 104 recruiting trials for “sickle-cell-beta-thalassemia-disease”
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia
👨⚕️ Tariq Ghafoor, FCPS,FRCP, National Institute of Blood and Marrow Transplant (NIBMT), Pakistan📍 9 sites📅 Started Jan 2024View details ↗
Sickle Cell Children's Exercise Study (SuCCESs)
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
👨⚕️ Pharmacosmos Clinical and non-clinical Department, Pharmacosmos A/S📍 1 site📅 Started Sep 2023View details ↗
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
RecruitingNCT06385886 ↗
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
👨⚕️ Julie Kanter, MD, University of Alabama, Birmingham (UAB)📍 9 sites📅 Started Jun 2023View details ↗
RecruitingNCT05991336 ↗
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
RecruitingNCT05810181 ↗
Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
👨⚕️ Liza-Marie Johnson, MD, MPH, MSB, St. Jude Children's Research Hospital📍 1 site📅 Started Jun 2023View details ↗
Tocilizumab for Acute Chest Syndrome
RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease
👨⚕️ Ann-Marie Murtagh, King's College Hospitals NHS Foundation Trust📍 1 site📅 Started Feb 2023View details ↗
A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
👨⚕️ Maria Cancio, MD, Memorial Sloan Kettering Cancer Center📍 6 sites📅 Started Feb 2023View details ↗
RecruitingNCT05748717 ↗
Arterial Function Parameters and Transcranial Doppler Velocity in Paediatric Patients With Sickle Cell Disease
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
RecruitingNCT05799118 ↗
Study of the Role of Genetic Modifiers in Hemoglobinopathies
👨⚕️ Petros Kountouris, PhD, Cyprus Institute of Neurology and Genetics📍 26 sites📅 Started Oct 2022View details ↗
RecruitingNCT05508932 ↗
Atrial Fibrillation in Beta-Thalassemia
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →